RT Journal Article
SR Electronic
T1 The effect of maternal pre-/early-pregnancy BMI and pregnancy smoking and alcohol on congenital heart diseases: a parental negative control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20203786
DO 10.1101/2020.09.29.20203786
A1 Taylor, Kurt
A1 Elhakeem, Ahmed
A1 Nader, Johanna Lucia Thorbjørnsrud
A1 Yang, Tiffany
A1 Isaevska, Elena
A1 Richiardi, Lorenzo
A1 Vrijkotte, Tanja
A1 de Moira, Angela Pinot
A1 Murray, Deirdre M
A1 Finn, Daragh
A1 Mason, Dan
A1 Wright, John
A1 Oddie, Sam
A1 Roeleveld, Nel
A1 Harris, Jennifer R
A1 Andersen, Anne-Marie Nybo
A1 Caputo, Massimo
A1 Lawlor, Deborah A.
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.29.20203786.abstract
AB Background Congenital heart diseases (CHDs) are the most common congenital anomaly. The causes of CHDs are largely unknown, but intrauterine mechanisms appear to be important. Higher prenatal body mass index (BMI), smoking and alcohol consumption are associated with increased risk of CHDs. Whether these are causal is unclear.Methods Seven European birth cohorts including 232,390 offspring were included. We applied negative exposure paternal control analyses to explore the intrauterine effects of maternal BMI, smoking and alcohol consumption during pregnancy, on offspring CHDs and CHD severity. We used logistic regression and combined estimates using a fixed-effects meta-analysis and compared maternal-specific confounder-adjusted associations to similarly adjusted associations of paternal exposures. If there is a causal intrauterine effect of a maternal pregnancy exposure, we would expect to see a maternal-specific association, with no (or weaker) association with the paternal exposure.Results There were 2,469 CHD cases (1.1%). The association of mean BMI with CHD was null and similar in mothers (adjusted OR per 1kg/m2: 1.00 (95%CI: 0.99, 1.02)) and fathers (OR: 1.01 (0.99, 1.03)). The analyses of BMI categories resulted in similar increased odds of CHD in overweight (mothers OR: 1.15 (1.01, 1.31) and fathers 1.10 (0.96, 1.27)) and obesity (mothers OR: 1.12 (0.93, 1.36) and fathers 1.16 (0.90, 1.50)). Maternal smoking was associated with increased odds of CHD (OR: 1.11 (0.97, 1.25)) but paternal smoking was not (OR: 0.96 (0.85, 1.07)). The difference increased when removing offspring with genetic/chromosomal defects (mothers OR: 1.15 (1.01, 1.32) and fathers 0.93 (0.83, 1.05)). The positive association with maternal pregnancy smoking appeared to be driven by non-severe CHD cases (OR: 1.22 (1.04, 1.44)). Associations with maternal (OR: 1.16 (0.52, 2.58)) and paternal (OR: 1.23 (0.74, 2.06)) moderate/heavy pregnancy alcohol consumption were similar.Conclusions We have shown that maternal, but not paternal, pregnancy smoking is associated with an increase in odds of offspring CHDs, primarily non-severe CHDs, providing evidence of an intrauterine effect. We found no strong evidence of an intrauterine effect of higher maternal BMI or alcohol consumption on offspring CHDs. Our findings provide further evidence for why smoking cessation is important during pregnancy.Competing Interest StatementD.A.L reports support from Roche Diagnostics and Medtronic Ltd for research unrelated to that presented here. All other authors declare no conflicts of interest.Funding StatementSee funding statement at the end of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Please refer to the Ethical Approval section at the end of the manuscript whereby a table includes formal information about ethical oversight separated by cohort.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA manuscript describing in detail the LifeCycle project can be found at: https://link.springer.com/article/10.1007/s10654-020-00662-z. The LifeCycle Project or EU Child Cohort Network do not own data, but bring data from other cohorts together via a federated data analysis platform. Ethical and legal responsibility for data management and security is maintained by the source studies or home institutions. The principal investigators or home institutions should always administer permission for external access to specific data on their server for addressing research questions. The EU Child Cohort Network cannot provide open access to researchers. The data sharing protocols and agreements will be updated regularly, according to new legal practices, such as the European General Data Protection Regulation 2016/679 (GDPR). All governance protocols will take not only the short-term, but also the long-term EU Child Cohort Network, beyond the LifeCycle Project duration, into account.